China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing for HSK21542, a Category 1 drug, in postoperative analgesia for abdominal surgery has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step forward in the development of HSK21542, positioning it for potential use in managing pain following surgical procedures.
Mechanism of Action and Clinical Potential
HSK21542 is a selective peripheral Kappa receptor agonist characterized by its high selectivity and affinity. The drug works by synergistically regulating potassium and calcium currents with the involvement of G protein. It effectively inhibits itching by blocking the transduction of itching signals and reducing the excitability of the dorsal root ganglion and peripheral sensory nerves, thereby decreasing the release of inflammatory factors and neurotransmitters. This mechanism holds promise for providing effective postoperative pain relief.
Previous Approval and Ongoing Development
Haisco Pharmaceutical previously obtained clinical trial approval for HSK21542 in chronic pruritus, demonstrating the drug’s potential in addressing different types of discomfort. The acceptance of the filing for review in postoperative analgesia further expands the potential applications of HSK21542, highlighting Haisco’s commitment to innovation in pharmaceutical solutions.-Fineline Info & Tech
